공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

탄산탈수효소 9(EC 4.2.1.1) : 파이프라인 리뷰

Carbonic Anhydrase 9 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 364843
페이지 정보 영문 50 Pages
가격
US $ 3,500 ₩ 4,009,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,018,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,027,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


탄산탈수효소 9(EC 4.2.1.1) : 파이프라인 리뷰 Carbonic Anhydrase 9 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 50 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

탄산탈수효소 9(EC 4.2.1.1)를 표적으로 한 치료제 개발 상황에 대해 분석했으며, 개발 단계, 약제 표적, 작용기서, 투여 경로 및 분자 종류별 분석, 치료제 개발에 참여하고 있는 기업 개요, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

탄산탈수효소 9(EC 4.2.1.1) 개요

탄산탈수효소 9(EC 4.2.1.1) : 개발중인 제품 - 개발 단계별

탄산탈수효소 9(EC 4.2.1.1) : 개발중인 제품 - 치료 분야별

탄산탈수효소 9(EC 4.2.1.1) : 개발중인 제품 - 적응증별

탄산탈수효소 9(EC 4.2.1.1) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

탄산탈수효소 9(EC 4.2.1.1) : 기업에서 개발중인 제품

탄산탈수효소 9(EC 4.2.1.1) : 대학/기관에서 개발중인 제품

탄산탈수효소 9(EC 4.2.1.1) : 치료제 평가

  • 단독요법/병용요법 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

탄산탈수효소 9(EC 4.2.1.1) 치료제 개발에 참여하고 있는 기업

  • Advaxis, Inc.
  • Akshaya Bio Inc.

약제 개요

탄산탈수효소 9(EC 4.2.1.1) : 휴지중인 프로젝트

탄산탈수효소 9(EC 4.2.1.1) : 개발이 중지된 제품

탄산탈수효소 9(EC 4.2.1.1) : 주요 뉴스와 프레스 릴리스

부록

KSM 16.08.10

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Akshaya Bio Inc, H2 2019
  • Pipeline by EstryX Pharma Ltd, H2 2019
  • Pipeline by Kalgene Pharmaceuticals Inc, H2 2019
  • Pipeline by SignalChem Lifesciences Corp, H2 2019
  • Pipeline by Telix Pharmaceuticals Ltd, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

According to the recently published report 'Carbonic Anhydrase 9 - Pipeline Review, H2 2019'; Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme encoded by the CA9 gene. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid.

The report 'Carbonic Anhydrase 9 - Pipeline Review, H2 2019' outlays comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Breast Cancer, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)
  • The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Overview
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Companies Involved in Therapeutics Development
  • Akshaya Bio Inc
  • EstryX Pharma Ltd
  • Kalgene Pharmaceuticals Inc
  • SignalChem Lifesciences Corp
  • Telix Pharmaceuticals Ltd
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drug Profiles
  • (acetazolamide + temozolomide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ESE-15-ol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLC-0111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLC-149 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CA9 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STX-140 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TX-250 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target CA9 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Dormant Products
  • Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 30, 2019: Telix Pharmaceuticals to launch Japanese Renal Cancer Imaging Study
  • Aug 20, 2019: First Australian patient dosed in ZIRCON phase III trial
  • Jul 19, 2019: Telix Pharmaceuticals: Japanese regulatory update for renal cancer imaging program
  • Jul 15, 2019: Telix Pharmaceuticals reports positive phase III meeting with the FDA
  • Jun 13, 2019: Telix Pharmaceuticals and Eczacibasi-Monrol sign manufacturing and distribution agreement
  • Jun 05, 2019: Heidelberg Pharma receives milestone payment from partner Telix
  • Mar 20, 2019: cGMP manufacturing of TLX250 complete
  • Oct 23, 2018: Telix commences ZIRCON phase III renal cancer imaging trial
  • Oct 17, 2018: Telix Selects RTM to Manufacture Kidney Imaging Program in Europe
  • Oct 15, 2018: Interim analysis of 89 Zr-TLX250-CDx bridging study ("ZIR - DOSE") demonstrates significantly improved patient dosimetry
  • Oct 15, 2018: Telix and Cyclotek Enter into Manufacturing Partnership for Kidney Cancer Imaging
  • Aug 23, 2018: Heidelberg Pharma: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
  • Jul 26, 2018: Telix Pharmaceuticals and JFE Progress japanese manufacturing partnership
  • Jun 25, 2018: Telix and Isologic conclude manufacturing agreement for North America
  • May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up Partner
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q